The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Prostate-specific membrane antigen (PSMA)–targeted imaging of metastatic prostate cancer (PCa) via small molecule inhibitors: Comparison to bone scan, CT/MRI, and 111In capromab.
R. E. Coleman
Honoraria - Molecular Insight Pharmaceuticals
Research Funding - Molecular Insight Pharmaceuticals
J. A. Barrett
Employment or Leadership Position - Molecular Insight Pharmaceuticals
Stock Ownership - Molecular Insight Pharmaceuticals
A. Hussain
Research Funding - Molecular Insight Pharmaceuticals
K. M. Slawin
Research Funding - Molecular Insight Pharmaceuticals
T. Armor
Employment or Leadership Position - Molecular Insight Pharmaceuticals
Stock Ownership - Molecular Insight Pharmaceuticals
N. D. LaFrance
Stock Ownership - Molecular Insight Pharmaceuticals
J. W. Babich
Employment or Leadership Position - Molecular Insight Pharmaceuticals
Stock Ownership - Molecular Insight Pharmaceuticals